Skip to main content
SCANCELL HOLDINGS PLC logo

SCANCELL HOLDINGS PLC — Investor Relations & Filings

Ticker · SCLP ISIN · GB00B63D3314 LEI · 2138008RXEG856SNP666 IL Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2018-02-15 Regulatory Filings
Country GB United Kingdom
Listing IL SCLP

About SCANCELL HOLDINGS PLC

https://www.scancell.co.uk/

Scancell Holdings PLC is a clinical-stage company developing novel active immunotherapies for the treatment of cancer. Its approach focuses on enhancing long-lasting, tumor-specific immunity to address significant unmet needs in oncology, particularly for hard-to-treat cancers. The company leverages its proprietary technology platforms, Immunobody®, Moditope®, and AvidiMab™, to create targeted, off-the-shelf therapies. The Immunobody® platform generates DNA-based immunotherapies, with its lead candidate, iSCIB1+, targeting advanced melanoma. The Moditope® platform develops peptide-based therapies, with a lead product showing encouraging Phase 2 data in a broad range of solid tumors. Scancell aims to deliver treatments that are safe, effective, easily administered, and accessible to patients.

Recent filings

Filing Released Lang Actions
Collaboration agreement with ISA Pharmaceuticals
Regulatory Filings Classification · 95% confidence The document begins with an 'RNS Number' and a date, indicating it is a regulatory announcement. The content describes a 'worldwide licensing and collaboration agreement' between two companies (ISA Pharmaceuticals and Scancell Holdings plc) regarding drug development (Modi-1 / AMPLIVANT®). This type of announcement, detailing a significant business transaction, partnership, or corporate development that is not a standard financial report (like 10-K or IR) or a specific insider trade/dividend notice, typically falls under general regulatory filings. Since it is a formal announcement disseminated via the RNS system and concerns a material business event, the most appropriate classification is Regulatory Filings (RNS), as it doesn't fit the more specific categories like CAP (Capital/Financing Update, which usually involves raising funds or debt structure changes) or TAR (M&A Activity, which implies a takeover/merger, not just a licensing deal). Given the RNS header and the nature of the announcement, RNS is the best fit.
2018-02-15 English
Publication highlights potential of SCIB1 therapy
Regulatory Filings Classification · 99% confidence The document begins with an 'RNS Number' and the date, indicating it is a regulatory announcement. The content discusses the publication of peer-reviewed research regarding their SCIB1 therapy, provides updated survival data from a clinical trial, and announces future plans for an IND application and a Phase 2 study. This is a general update on clinical progress and scientific validation, not a formal financial report (like 10-K or IR) or a specific announcement like a dividend or management change. Since it is a formal announcement disseminated via the RNS system that details scientific/clinical progress rather than a specific financial outcome (like ER) or a general corporate action, the most appropriate classification is the general regulatory filing category, RNS, as it serves as a broad update to the market.
2018-02-12 English
European patent application allowed for grant
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated February 9, 2018. The content announces a specific corporate event: the European Patent Office's intention to grant a patent for the Moditope® platform. This is a material, non-financial announcement released via the Regulatory News Service (RNS). Since it is a specific regulatory announcement that doesn't fit into categories like Director's Dealing (DIRS), Dividend (DIV), or Capital Change (CAP), and it is not a full report (like 10-K or IR), the most appropriate classification is the general regulatory announcement category, RNS, which serves as a catch-all for such official disclosures. However, upon reviewing the definitions, the content is specifically about Intellectual Property (IP) protection and expansion. While RNS is a valid general category, the document details the allowance of a European patent application, which is a form of Intellectual Property disclosure. Given the specific nature of the announcement (patent grant intention), it strongly relates to IP strategy. Since there is no specific 'IP' code, and the document is a direct regulatory announcement (indicated by RNS Number), RNS is the most fitting general regulatory category. If 'IP' were an option, it might be considered, but based on the provided list, RNS is the best fit for a standard regulatory news service release detailing a non-financial operational milestone.
2018-02-09 English
Scancell member of team shortlisted for CRUK award
Regulatory Filings Classification · 99% confidence The document begins with an 'RNS Number' and the date, indicating it is a regulatory news service announcement. The content describes Scancell Holdings Plc being shortlisted for a Cancer Research UK Grand Challenge award, detailing the scientific proposal and team involved. This is a general corporate announcement regarding a scientific achievement and potential funding, not a formal financial report (like 10-K or IR), a management change (MANG), or a dividend notice (DIV). Since it is a general, material, non-financial announcement distributed via the RNS system, and it doesn't fit into the more specific categories like DIRS, CAP, or LTR, the most appropriate classification is the general regulatory filing fallback category, RNS.
2018-02-08 English
Director/PDMR Shareholding
Director's Dealing Classification · 98% confidence The document is an announcement released via RNS (RNS Number : 5508D) on 01 February 2018. The content explicitly details the 'Grant of Options to Directors' and other staff members, including specific details about the number of options, exercise price, vesting schedules, and changes to existing option plans. Crucially, it includes a section titled 'NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM' (PDMR transactions). This structure—announcing insider transactions (director option grants) via an RNS feed—is characteristic of insider dealing disclosures or specific regulatory filings related to executive compensation/share dealings. While it involves directors, it is not a formal remuneration report (DEF 14A) or a general director's dealing report (DIRS) which usually reports sales/purchases of existing shares. However, the core subject is the grant of options to directors/executives, which falls under insider transactions related to compensation/share holdings. Given the options provided, 'Director's Dealing' (DIRS) is the closest fit for reporting transactions involving directors' equity interests, even if it's an option grant rather than a sale/purchase of common stock. Alternatively, since it is a formal regulatory announcement via RNS detailing executive equity changes, it could be classified as a general Regulatory Filing (RNS). Since the content is highly specific to executive equity transactions, DIRS is a strong candidate, but the format strongly suggests a mandatory disclosure under MAR/RNS rules. Given the explicit tables detailing PDMR transactions (grant of options), DIRS (Director's Dealing) is the most specific fit for the *content* of the transaction, even if the *delivery mechanism* is RNS.
2018-02-01 English
Half-year Report
Earnings Release Classification · 99% confidence The document explicitly states, 'Interim Results for the six months ended 31 October 2017' and provides detailed financial performance metrics (Loss for the 6-month period of £2.02 million) and operational highlights for that period. The reporting period is six months, which signifies an interim report, not a full annual report (10-K). The document is comprehensive, containing financial tables (though truncated) and management commentary, making it more than just an 'Earnings Release' (ER). Therefore, it fits the definition of an Interim / Quarterly Report (IR). The RNS number suggests it was filed via a regulatory news service, but the content itself is the detailed interim report. H1 2017
2018-01-30 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.